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AbstrAct
Double-hit B-cell lymphoma is a common designation for a group of tumors 
characterized by concurrent translocations of MYC and BCL2, BCL6, or other genes. 
The prognosis of concurrent MYC and BCL6 translocations is not well known. In 
this study, we assessed rearrangements and expression of MYC, BCL2 and BCL6 
in 898 patients with de novo diffuse large B-cell lymphoma treated with standard 
chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone plus 
rituximab). Neither BCL6 translocation alone (more frequent in activated B-cell like 
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INtrODUctION
Diffuse large B-cell lymphoma (DLBCL) is the 
most common type of non-Hodgkin lymphoma and 
has heterogeneous biologic features. Chromosomal 
rearrangements, the biologic and diagnostic hallmarks 
of some other types of B-cell lymphoma, also occur in 
DLBCL. The most common chromosomal rearrangements 
in DLBCL are those involving chromosomal gene loci 
8q24/MYC, 18q21/BCL2, and 3q27/BCL6 [1, 2]. MYC 
rearrangement, a disease-initiating event in Burkitt 
lymphoma (BL), can be observed in approximately 10% 
of de novo DLBCL and correlates with a poorer outcome 
[3-7]. However, MYC rearrangement alone may not 
explain the poor prognosis of patients with DLBCL that 
carry MYC rearrangement plus another chromosomal 
rearrangement. The designation double-hit lymphoma 
(DHL) has been used for a B-cell lymphoma carrying 
a MYC/8q24 rearrangement in combination with a 
rearrangement involving either BCL2, BCL6, or rarely 
other known oncogenes [2, 8, 9].
 By far, the most common and well-studied type 
of DHL is characterized by concurrent MYC and BCL2 
rearrangements (MYC/BCL2 DHL), occurring in about 5% 
of all cases of DLBCL [10, 11]. As key regulators of cell 
proliferation and apoptosis, respectively, MYC and BCL2 
may act synergistically to drive the pathogenesis of MYC/
BCL2 DHL [12]. Clinically, patients with MYC/BCL2 
DHL often exhibit adverse prognostic factors, such as 
high serum lactate dehydrogenase (LDH) level, advanced 
stage of disease, extranodal involvement, and a high 
proliferation index with a median value of 90%. There 
is a general consensus that MYC/BCL2 DHL represents 
a treatment-refractory subgroup with a median survival 
of approximately 8 months [13-20]. Despite the dismal 
outcome of patients with MYC/BCL2 DHL, almost all of 
these tumors arise within the germinal center B cell-like 
(GCB) subtype, a generally favorable prognostic subtype, 
illustrating a discordance between clinical behavior and 
cell of origin (COO) subtypes [1, 15, 17, 21].
 As an extension of the concept of MYC/BCL2 
DHL, the concept of “double protein lymphoma (DPL)” 
has been developed in recent years referring to DLBCL 
with coexpression of MYC and BCL2 detected by 
immunohistochemistry (IHC), regardless of activation 
mechanisms. MYC/BCL2 DPL is more common 
than MYC/BCL2 DHL and accounts for 18-44% of 
DLBCL cases and might result from gene amplification, 
transcriptional dysregulation or both [11, 22-26]. A 
series of studies have shown that patients with MYC/
BCL2 DPL have a significantly poorer outcome than 
patients who express only one or neither protein, with a 
5-year progression-free survival (PFS) of 25% following 
R-CHOP treatment [11, 22]. Interestingly, unlike MYC/
BCL2 DHL which is mainly observed in the GCB subtype, 
MYC/BCL2 DPL is more common in the activated-B cell-
like (ABC) subtype and may largely contribute to inferior 
survival via NF-κB pathway activation [23].
 According to the concept of DHL used currently, 
another type of DHL is MYC/BCL6 DHL with concurrent 
MYC and BCL6 rearrangements [1, 2]. However, there 
are far less data available for MYC/BCL6 DHL, in part 
because of its rarity. BCL6 is a transcriptional suppressor 
required for germinal center formation with numerous 
transcriptional targets, including the cell cycle regulator 
CCND2 and MYC, which explains downregulation 
of MYC in normal germinal center B-cells [27-29]. 
Studies by others have suggested that BCL6 expression 
is associated with better survival of DLBCL patients 
[24, 30]. The frequency and the prognostic impact of 
concurrent MYC/BCL6 rearrangements and MYC/BCL6 
protein coexpression in DLBCL remain unclear. 
In this study, we assessed the frequency, 
clinicopathologic features, and the prognostic impact of 
concurrent MYC/BCL6 rearrangements or MYC/BCL6 
coexpression in a large cohort of de novo DLBCL patients 
treated with R-CHOP, in comparison to MYC/BCL2 
rearrangements and MYC/BCL2 coexpression. The study 
evaluated the role of each genetic translocation separately 
and in combinations, providing reliable conclusion and 
practical recommendations for diagnostic workup and 
prognostic prediction.
diffuse large B-cell lymphoma) nor in combination with MYC translocation (observed in 
2.0% of diffuse large B-cell lymphoma) predicted poorer survival in diffuse large B-cell 
lymphoma patients. Diffuse large B-cell lymphoma patients with MYC/BCL6 co-expression 
did have significantly poorer survival, however, MYC/BCL6 co-expression had no effect on 
prognosis in the absence of MYC/BCL2 co-expression, and had no additive impact in MYC+/
BCL2+ cases. The isolated MYC+/BCL6+/BCL2− subset, more frequent in germinal center 
B-cell like diffuse large B-cell lymphoma, had significantly better survival compared with 
the isolated MYC+/BCL2+/BCL6− subset (more frequent in activated B-cell like diffuse large 
B-cell lymphoma). In summary, diffuse large B-cell lymphoma patients with either MYC/
BCL6 rearrangements or MYC/BCL6 co-expression did not always have poorer prognosis; 
MYC expression levels should be evaluated simultaneously; and double-hit B-cell lymphoma 
needs to be refined based on the specific genetic abnormalities present in these tumors.
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rEsULts
Overall frequency and distribution
The median age of the study population was 64 
years (range, 16-95). The median follow-up time was 58.9 
months (range, 1-187 months). Among the 898 cases, 
469 (52%) were GCB and 429 (48%) were determined 
to be GCB and ABC subtype, respectively. The complete 
response rate to R-CHOP therapy was 75%. As shown in 
Table 1, rearrangements of MYC, BCL2, and BCL6 were 
detected in 71 (11.8%) of 600, 94 (13.6%) of 690, and 
145 (23.1%) of 628 cases, respectively. MYC and BCL2 
rearrangements were detected predominantly in GCB 
subtype (P = 0.0005 and P < 0.0001, respectively) whereas 
BCL6 rearrangement was more frequently observed 
in the ABC subtype (P = 0.0002). MYC/BCL2, MYC/
BCL6, and BCL2/BCL6 concurrent rearrangements were 
identified in 20 (2.8%), 14 (2%), and 21 (2.9%) patients, 
respectively. Both MYC/BCL2 and BCL2/BCL6 concurrent 
rearrangements were observed mostly in the GCB subtype 
(MYC+/BCL2+: P < 0.0001; BCL2+/BCL6+: P = 0.0045) 
whereas MYC/BCL6 concurrent rearrangements were 
observed in two COO subtypes (9 GCB, 5 ABC) without 
significantly difference in frequency (P = 0.37). 
Using immunohistochemistry 249 (30.2%), 439 
(51.7%), and 555 (62.6%) patients had high levels of 
MYC (≥70%), BCL2 (≥70%), and BCL6 ( > 50%) 
expression, respectively. MYC expression was similarly 
distributed between GCB and ABC subtypes (P = 0.17) 
whereas BCL2 and BCL6 expression were significantly 
more common in the ABC and GCB subtypes, respectively 
(both P < 0.0001), in contrast to the association of 
their gene translocations with GCB and ABC subtype 
respectively. MYC+/BCL2+, MYC+/BCL6+, and BCL2+/
BCL6+ coexpression were observed in 146 (17.6%), 178 
(21.7%), and 282 (33.4%) cases, respectively. Unlike the 
predominance of MYC+BCL2+ coexpression in the ABC 
subtype (P = 0.0079), both MYC+/BCL6+ and BCL2+/
BCL6+ coexpression were equally distributed between the 
two COO subtypes (P = 0.35 and P = 0.47, respectively). 
All MYC protein positive patients were further stratified 
into three subgroups: MYC+/BCL2+/BCL6- (MYC+/BCL2+ 
coexpression, BCL6-), MYC+/BCL6+/BCL2- (MYC+/
BCL6+ coexpression, BCL2-) and MYC+/BCL2+/BCL6+ 
coexpression. The MYC+BCL2+BCL6- subgroup was 
predominantly of ABC subtype (P = 0.0019), whereas 
the MYC+BCL6+BCL2- subgroup was more commonly of 
table 1: Frequencies of MYC, BCL2 and BCL6 gene translocations and protein overexpression, and multivariate 
survival analysis 
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GCB subtype (P = 0.011) (Table 1).
clinicopathologic features of DLbcL with 
concurrent rearrangement and coexpression
The clinicopathologic features of patients in 
the study cohort with or without concurrent gene 
rearrangements and protein coexpression are listed in 
Table 2. DLBCL patients with MYC/BCL2 rearrangements 
more frequently had large tumors (P = 0.02) and a lower 
complete response rate (P = 0.0033), and commonly 
the tumors were of GCB subtype (P < 0.0001). No 
clinicopathologic features were significantly different 
between DLBCL patients with concurrent MYC/BCL6 
rearrangements versus patients without MYC/BCL6 
concurrent rearrangement, although larger tumor size was 
of borderline significance (P = 0.058). 
Patients with MYC+/BCL2+ coexpression were 
more often of older age (P = 0.0016) and more often 
had advanced disease stage (P < 0.0001), extranodal 
involvement (P = 0.0026), large tumor size (P = 0.03), 
International Prognostic Index score > 2 (P < 0.0001), 
low complete response rate (P = 0.0071), and high Ki-
67 (P = 0.0002), and the lymphoma was more often of 
ABC subtype (P = 0.0079). Patients with MYC+/BCL6+ 
coexpression were associated with advanced disease stage 
(P = 0.015), extranodal sites (P = 0.011), low complete 
response rate (P = 0.0023) and high Ki-67 index (P = 
0.0017). When MYC+/BCL2+/BCL6- and MYC+/BCL6+/
BCL2- subgroups were isolated from the MYC+/BCL2+ 
and MYC+/BCL6+ patients respectively, MYC+/BCL2+/
BCL6- tumors were more often of ABC subtype, whereas 
MYC+/BCL6+/BCL2- tumors were more commonly of 
GCB subtype (P = 0.0003) (Table 2). 
Prognostic impact of concurrent rearrangements 
of MYC, BCL2, and BCL6 in DLbcL
We first assessed the prognostic impact of 
rearrangements of MYC, BCL2, and BCL6 in DLBCL 
(Figure 1 and Supplementary Figure S1). Both MYC and 
BCL2 rearrangements correlated to a poorer survival in 
the whole cohort (P = 0.003 for MYC, Figure 1A; P = 
0.046 for BCL2, Figure 1B) and in the GCB subtype (P < 
0.0001 for MYC, Figure 1D; P < 0.0009 for BCL2, Figure 
1E) but not in the ABC subtype (Figure 1G-1H). BCL6 
Figure 1: Univariate analysis for patients with DLbcL with MYC, BCL2, and BCL6 rearrangemnts in the overall-, 
Gcb, and Abc groups. A.-b., D.-E, G.-H. MYC and BCL2 rearrangements correlated with significantly poorer overall survival in 
overall and GCB- but not ABC-DLBCL. c., F., I. BCL6 translocation did not correlate with poorer overall survival. 
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translocation, by contrast, did not correlate with poorer 
survival for either the whole cohort (P = 0.33, Figure1C) 
or in the GCB (P = 0.87, Figure 1F) and ABC (P = 0.32, 
Figure 1I) subtypes.
We then assessed the prognostic impact of 
concurrent rearrangements in DLBCL. Patients with MYC/
BCL2 translocations had a worse survival than patients 
with MYC rearrangement alone (overall survival [OS]: P 
= 0.025; PFS: P = 0.012, Figure 2A-2B). However, no 
difference was observed in OS and PFS between DLBCL 
patients with MYC/BCL6 rearrangement versus DLBCL 
patients with only MYC rearrangement (Figure 2C-2D). 
Figure 2: A.-b. The prognostic significance of MYC rearrangements in DLBCL depends on BCL2 rearrangement. c.-D. BCL6 
rearrangement had no additive effect to MYC rearrangements. E.-F. BCL6 translocation had no additive effect to BCL2 rearrangements. 
G.-H. MYC expression levels appeared to impact the survival of MYC+/BCL6+ rearranged DLBCL with marginal P values probably due 
to the small case numbers.
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There was also no difference in OS and PFS between 
patients with DLBCL with BCL2/BCL6 rearrangement 
versus DLBCL with only BCL2 rearrangement (Figure 
2E-2F). Notably the survival of patients with MYC/BCL6 
rearrangement appeared to be affected by MYC expression 
levels (Figure 2G-2H).
The prognostic differences between patients with 
concurrent rearrangements of MYC/BCL2, MYC/BCL6, 
BCL2/BCL6 versus the remaining DLBCL patients 
are shown in Figure 3. Only concurrent MYC/BCL2 
rearrangements correlated with significantly poorer 
survival (Figure 3A-3B). Additional BCL6 translocation 
(triple-hit, n = 5, 26% of 19 MYC+/BCL2+ cases with 
BCL6 translocation status available) had no synergistic 
effect with concurrent MYC/BCL2 rearrangements and, on 
the contrary, attenuated the adverse impact of concurrent 
MYC/BCL2 rearrangements (Figure 3G-3H).
Prognostic impact of coexpression of MYc, 
bcL2, and bcL6 in DLbcL
The prognostic impact of protein expression 
of MYC, BCL2, and BCL6 is shown in Figure 4 and 
Supplementary Figure S2. BCL6 expression in DLBCL 
did not correlate with poorer patient survival, either in 
the whole group or in COO subtypes (Figure 4C, 4F, and 
4I). In contrast, MYC+ or BCL2+ expression in DLBCL 
correlated with significantly poorer survival for the overall 
patient cohort (P < 0.0001, Figure 4A-4B) and for patients 
with GCB (MYC+: P < 0.0001, Figure 4D; BCL2+: P = 
0.004, Figure 4E) and ABC subtypes of DLBCL (MYC+: 
P = 0.032, Figure 4G; BCL2+: P < 0.0001, Figure 4H).
Our results further showed that MYC+/BCL2+ 
(P < 0.0001, Figure 5A, Supplementary Figure S3A), 
MYC+/BCL6+ (OS: P = 0.0001, Figure 5C; PFS: P 
= 0.0002, Supplementary Figure S3C), and BCL2+/
BCL6+ (OS: P = 0.014, Figure 5E; PFS: P = 0.033, 
Supplementary Figure S3E) coexpression correlated with 
significantly poorer survival in the overall cohort. The 
inferior survival of patients MYC+/BCL2+ and MYC+/
BCL6+ DLBCL compared with all other DLBCL patients 
was significant for both the GCB and ABC subtypes, 
whereas BCL2+/BCL6+ only correlated with poorer OS 
for patients with ABC-DLBCL (Supplementary Figure 
S4). MYC expression showed dependence and synergy 
only with BCL2 expression (Figure 5B, Supplementary 
Figure S3B); BCL6 expression had no additive adverse 
impact in patients with MYC+, BCL2+ or MYC+/BCL2+ 
DLBCL (Figure 5D, 5F-5G, Supplementary Figure S3D, 
table 2: clinical characteristics of patients with concurrent MYC, BCL2 or BCL6 translocations and MYc, bcL2 or 
bcL6 protein co-expression
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S3F-S3G). Patients with MYC+/BCL2+ DLBCL but not 
MYC+/BCL6+ DLBCL had poorer survival (Figure 5G, 
Supplementary Figure S3G). The poor prognosis of 
patients with MYC+/BCL6+ DLBCL was attributable to 
the poorer survival of MYC+/BCL2+ DLBCL patients.
We further evaluated the survival of patients with 
isolated MYC+/BCL2+/BCL6- (i.e., BCL6- DPL) versus 
isolated MYC+/BCL6+/BCL2- (i.e., BCL2- DPL) DLBCL. 
Patients with isolated MYC+/BCL6+ DLBCL had favorable 
survival compared with isolated MYC+/BCL2+ DLBCL 
patients (OS: P = 0.004, Figure 5H; PFS: P < 0.0001, 
Supplementary Figure S3H). 
Gene expression signatures of concurrent MYC, 
BCL2, and BCL6 rearrangements and isolated 
MYc+bcL2+ and MYc+bcL6+ coexpression
To better understand the molecular mechanisms of 
the effects on prognosis, we compared the GEP of patients 
with concurrent MYC/BCL2 or MYC/BCL6 rearrangements 
with the remaining patients. Only MYC/BCL2 rearranged 
DLBCL showed a distinctive GEP signature, whereas 
concurrent MYC/BCL6 rearranged DLBCL did not 
show DEGs compared with MYC rearranged DLBCL or 
the remaining DLBCL patients. The GEP signature of 
concurrent MYC/BCL2 rearranged DLBCL included 24 
upregulated genes and 14 downregulated genes at the 
false discovery rate threshold of 0.01 (Table. 3A, Figure 
5A). These genes were involved in signaling (upregulation 
of BMP3, SWAP70, and CELSR1, and downregulation of 
PLA2G7 and DOCK10), cell proliferation (upregulated 
STRBP and MUC4), metabolism (eight upregulated 
genes), apoptosis (TMEM49, CFLAR, CARD16 and 
CASP1), transcription factors and genes related to cell 
adhesion, extracellular matrix, and migration (MYO3B, 
SLAMF7, SILEC10/12, TPM4, and SRGN). 
Comparison of the GEP of MYC+ BCL6+ versus 
MYC+BCL2+ DLBCL did not show significant DEGs. 
We further compared the GEP of isolated MYC+BCL2-
BCL6+ DLBCL versus isolated MYC+BCL2+BCL6- 
DLBCL, which resulted in 36 DEGs at the false 
discovery rate threshold of 0.05 (Table 3B, Figure 6B). 
Upregulated genes in MYC+BCL2-BCL6+ compared 
with MYC+BCL2+BCL6- included BCL6, a proliferation 
signature (MYBL1, NEK6, BRWD1 [bromodomain and 
WD repeat domain containing 1], SFRS15, HMGN1, 
and TMPO), MSH6 involved in DNA repair, DNAJC10 
which promotes apoptotic in response to endoplasmic 
reticulum stress, various signaling genes including 
PIK3CG (PI3K catalytic subunit gamma), STAP1 (B-cell 
receptor signaling) SORL1, RFTN1, GNA13, SWAP70, 
and ANKRD13A, and genes involved in actin cytoskeleton 
regulation and migration (MARCKSL1, VNN2, OSBPL3, 
ACTR2 and etc.). Comparably, upregulated genes in 
MYC+BCL2+BCL6- included signatures of apoptosis 
(antiapoptotic BCL2, and paradoxically proapoptotic, 
CASP10), glutamine metabolism (ALDH4A1) , indicating 
that abnormal dysregulation of apoptotic and proliferation 
pathways are critical in patients with MYC+BCL6+BCL2−. 
In contrast, such signaling and molecular defects were 
not seen in patients with MYC+BCL6−BCL2+. The 
observations provide molecular basis for the difference 
of outcome and survival between these two groups of 
DLBCL patients.




In the literature B-cell lymphomas with concurrent 
MYC/BCL2 or MYC/BCL6 rearrangements are grouped 
together as double-hit B-cell lymphomas [1, 2]. Patients 
with MYC/BCL2 DHL have responded poorly to all 
traditional chemotherapy regimens and have extremely 
poor outcomes [1, 10, 11]. However, most of what we 
know about double-hit B-cell lymphoma is derived from 
studies of the most common form, MYC/BCL2 DHL. In 
contrast, very little has been published on DLBCL patients 
with concurrent MYC/BCL6 rearrangements. The findings 
in this study for a group of DLBCL patients treated with 
R-CHOP suggest that patients with concurrent MYC/BCL6 
rearrangements do not have a poorer prognosis and that 
grouping these tumors with other forms of DHL could lead 
to inappropriate therapy.
Figure 3: A.-b. Concurrent MYC/BCL2 rearrangements correlated with significant poorer overall survival. c.-D. Concurrent MYC+/
BCL6+ rearrangements did not correlate with poorer overall survival. E.-F. Concurrent BCL2+/BCL6+ rearrangements did not correlate 
with poorer overall survival. G.-H. BCL6 attenuated the adverse prognostic impact of MYC+/BCL2+ double-hit lymphoma.
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In this large cohort of 898 cases of de novo DLBCL, 
rearrangements of MYC, BCL2, and BCL6 were found in 
11.8%, 13.6% and 23.1% of cases, respectively. BCL6 
rearrangements were more frequently observed in the 
ABC subtype whereas MYC and BCL2 rearrangements 
were more frequently observed in the GCB subtype. 
Concurrent MYC/BCL6 and MYC/BCL2 rearrangements 
were observed in 2.0% and 2.8% of DLBCL cases, 
respectively. MYC/BCL2/BCL6 triple-hit was observed 
in 38% of MYC/BCL6 and 26% of MYC/BCL2 double-
hit cases. The frequencies of MYC, BCL2, and BCL6 
rearrangement and concurrent MYC/BCL2 rearrangements 
are similar to those reported in DLBCL in earlier studies 
[10, 11, 31-34]. 
 In this study, DLBCL patients with concurrent MYC/
BCL6 rearrangements did not have a poorer prognosis. 
The notion that concurrent MYC/BCL6 rearrangements 
in DLBCL is not an indication of aggressive lymphoma 
was further substantiated by the lack of a distinctive GEP 
signature for MYC/BCL6 rearranged DLBCL although 
BCL6 was overexpressed in almost all MYC/BCL6 
rearranged patients except one case with an IHC of 30%. 
These phenomena might be explained by a previous 
finding that up to 43% of BCL6 translocations involved 
non-IG loci showing complex gene expression patterns 
[35], limited case numbers, and 36% of MYC/BCL6 cases 
showing low MYC expression levels (Figure 2G-2H). 
In contrast, MYC/BCL2 rearranged DLBCL correlated 
with significantly poorer survival, and was associated 
with a distinctive GEP signature suggesting increased 
proliferation, growth and metabolism and decreased 
apoptosis pathway (our results showed downregulation of 
both pro- and anti-apoptotic genes).
In the MD Anderson Cancer Center experience 
with 52 DHL patients tested for BCL6, 24 patients with 
BCL6 gene abnormality (translocation or amplification, 
n = 15 and n = 9 respectively. Among them, 14 patients 
had MYC/BCL2/BCL6 triple-hit) showed slightly better 
survival than other patients with DHL (hazard ratio: 0.59, 
95% confidence interval: 0.21-1.69, P = 0.33) [36]. Ueda 
et al. presented a case report consistent with our results, 
in which a person having DLBCL with concurrent MYC, 
BCL2, and BCL6 rearrangements achieved complete 
remission after chemoradiotherapy for two years [37]. 
A recent study reported the largest DHL series including 
41 cases with BCL6 rearrangement, in which patients’ 
OS was not significantly affected by whether the DHL 
was MYC/BCL2 or MYC/BCL6 (P = 0.537). However, 
25 (58.5%) of the 41 MYC/BCL6 patients also had BCL2 
rearrangement (triple-hit) [38]. In contrast, in another 
study, MYC/BCL6 (n = 13) showed significantly worse 
survival than MYC/BCL2 DHL (n = 20) after exclusion 
of triple-hit lymphoma [39]. These MYC/BCL6 DHL 
showed a trend toward higher MYC mRNA expression and 
a distinct gene expression profile compared to MYC/BCL2 
DHL. In a smaller study reported by Pillai et al. B-cell 
Figure 4: Univariate analysis for DLbcL patients with MYc, bcL2 and bcL6 protein expression in the overall-, 
Gcb, and Abc-DLbcL. A.-b., D.-E., G.-H. MYC and BCL2 protein expression correlated with significantly poorer overall survival 
in overall, GCB- and ABC-DLBCL. c., F., I. BCL6 overexpression did not correlate with poor survival. 
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lymphoma with concurrent MYC/BCL6 rearrangements 
was associated with aggressive clinical course and poor 
survival [40]. A possible explanation for the discrepancy 
is patient selection. In the study by Pillai et al, patients 
with BL, BL-like lymphoma, and primary effusion 
lymphoma were also included. Moreover, the median age 
of their patients was 83 years and only one of six patients 
with adequate information received chemotherapy in 
combination with rituximab [40]. In this study, all patients 
met morphologic and immunophenotypic criteria for 
DLBCL with a median patient age of 64 years, which 
is comparable to that of patients with DLBCL without 
concurrent MYC/BCL6 rearrangements, and all patients 
were treated with standard R-CHOP therapy.
Recently, the concept of MYC/BCL2 rearranged 
DHL has been extended to MYC and BCL2 protein 
Figure 5: A., c., E. Patients with DLBCL and MYC/BCL2, BCL6/MYC or BCL2/BCL6 co-expression had significantly poorer overall 
survival in the DBLCL cohort. b. BCL2 overexpression had a synergetic effect with MYC overexpression and the adverse prognostic impact 
of MYC depended on BCL2 overexpression. D. BCL6 expression had no synergetic effect with MYC expression. F. BCL6 expression 
appeared to attenuate the adverse prognostic impact of BCL2 overexpression. G. The poorer overall survival of MYC+BCL6+ patients was 
due to the poor survival of MYC+BCL2+ patients. H. Isolated MYC+BCL6+ versus MYC+BCL2+ double-positive DLBCL had significantly 
better patient survival. 
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coexpression [11, 22, 23]. These studies showed that 
patients with DLBCL with MYC/BCL2 double-positive 
(by immunohistochemistry) also have a dismal prognosis, 
regardless of the status of MYC or BCL2 rearrangement 
[11, 22, 23]. In this study, DLBCL patients with MYC/
BCL6 coexpression showed a significantly poorer survival 
than DLBCL patients without MYC/BCL6 coexpression. 
However, this prognostic effect was significant only in 
Figure 6: Gene expression signature for MYC/BCL2 double-hit DLbcL (A) and comparison of MYc+bcL2+ bcL6− 
versus MYc+bcL2−bcL6+ translocation in DLbcL (b).
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the presence of DLBCL with MYC/BCL2 coexpression. 
The isolated MYC+BCL2-BCL6+ (from all MYC+BCL6+) 
subgroup had significantly better patient survival 
compared with the MYC+BCL2+BCL6- (from all 
MYC+BCL2+) subgroup. Previous studies also suggested 
that BCL6 expression is associated with favorable survival 
in patients with DLBCL [24, 30, 41, 42].
There is a biologic basis that may explain the lack of 
significantly adverse prognostic impact of recurrent MYC/
BCL6 rearrangements and MYC/BCL6 coexpression. 
BCL6 represses CCND2 and MYC [27-29, 43]; we have 
recently shown that MYC expression levels significantly 
impact the prognosis of MYC rearranged DLBCL [44], 
and our multivariate analysis suggested BCL6 expression 
correlated with favorable survival (P = 0.048 for OS 
and P = 0.016 for PFS, Table 1), therefore the adverse 
prognostic impact of MYC might have been diminished 
by high BCL6 expression in these cases. In addition to the 
potential role of BCL6, the GEP signature of MYC+BCL2-
BCL6+ DLBCL suggested DNA repair and proapoptosis, 
in contrast with the upregulation of antiapoptotic BCL2 
in MYC+BCL2+BCL6- DLBCL. Interestingly, MYBL1 
and LIMD1 were also significantly upregulated in 
our MYC+BCL2-BCL6+ (associated with GCB) and 
MYC+BCL2+BCL6- (associated with ABC) DLBCL 
subgroup respectively, which is in consistent with the 
correlations between a novel two-gene expression index, 
“LIMD1-MYBL1 Index”, and GCB/ABC subtypes and 
clinical outcome [45, 46].
In summary, DLBCL patients with concurrent MYC/
BCL6 rearrangements are not necessarily associated with 
an inferior prognosis when treated with R-CHOP therapy, 
unlike DLBCL patients with concurrent MYC/BCL2 
rearrangements, probably due to different pathogenesis 
and MYC expression levels. In addition, DLBCL patients 
with MYC/BCL6 coexpression did have an inferior 
prognosis, but only in the presence of MYC/BCL2 
coexpression, and therefore MYC/BCL6 coexpression 
seems to be of less prognostic importance [46]. These 
data support the notion that DLBCL with concurrent MYC/
BCL6 rearrangements and DLBCL with MYC/BCL2 DHL 
are not equivalent prognostically. These results suggest 
that the concept of double-hit lymphoma needs to be 
refined. The grouping of cases of DLBCL with concurrent 
MYC/BCL6 rearrangements with cases of DLBCL with 
MYC/BCL2 rearrangements may lead to over treatment of 
MYC/BCL6 rearranged DLBCL patients. 
PAtIENts, MAtErIALs AND MEtHODs
Patients
A cohort of 898 patients with de novo DLBCL 
treated with standard rituximab, cyclophosphamide, 
doxorubicin, vincristine and prednisolone (R-CHOP) 
therapy was collected as part of The International DLBCL 
Rituximab-CHOP Consortium Program Study [33,46]. All 
patients were diagnosed according to the World Health 
Organization (WHO) classification system and received 
treatment between 1998 and 2010. Cases were excluded 
if patients had a history of low-grade B-cell lymphoma; 
human immunodeficiency virus infection; or primary 
mediastinal, cutaneous B cell lymphoma, or central 
nervous system DLBCL. This study was approved by the 
Institutional Review Boards of each participating center, 
and the comprehensive collaborative study was approved 
by the Institutional Review Board at The University of 
Texas MD Anderson Cancer Center. 
tissue microarray, immunohistochemistry and 
fluorescence in situ hybridization
Construction of tissue microarrays, IHC staining 
procedures on tissue microarray sections, and scoring 
criteria for MYC, BCL2 and BCL6 have been described 
previously [23, 44, 47]. MYC (clone Y69; Epitomics, 
Burlingame, CA) and BCL6 (clone LN22; Leica 
Microsystems, Buffalo Grove, IL) expression showed a 
distinct nuclear pattern and BCL2 (clone 124; DAKO, 
Denmark) expression exhibited a cytoplasmic pattern. 
Cutoffs for MYC, BCL2 and BCL6 overexpression are 
determined as ≥70%, ≥70%, and > 50% respectively based 
on survival analysis as described previously, and cutoffs 
and positivity rates reported by other study groups.
Interphase fluorescence in situ hybridization (FISH) 
analysis was performed using formalin-fixed, paraffin-
embedded tissue sections and BCL2 and BCL6 dual-color, 
break-apart probes (Vysis), IGH/MYC/CEP8 tricolor dual-
fusion probes (Vysis) and a locus specific MYC dual-color 
break-apart probe (Vysis) as described previously [47].
Gene expression profiling and COO classification 
Gene expression profiling (GEP) was performed 
on formalin-fixed, paraffin-embedded tissue samples 
using Affymetrix GeneChip HG-U133 Plus Version 2.0 
(Affymetrix, Santa Clara, CA) as described in an earlier 
study [47]. The CEL files are deposited in the National 
Center for Biotechnology Information Gene Expression 
Omnibus repository (GSE#31312).61 The microarray 
data were quantified and normalized by the frozen robust 
multiarray analysis (RMA) algorithm [48]. Differential 
expression gene (DEG) analysis was performed using 
multiple t-tests [31, 47]. Cell-of-origin classification into 
either GCB or ABC subtypes was achieved by using either 
GEP (n = 497) or IHC methods (n = 401) according to 




Clinical and laboratory features of DLBCL 
patients at the time of presentation according to different 
subgroups were compared using the chi-squared test and 
the Spearman rank correlation test. Overall survival  (OS) 
was calculated from the date of diagnosis to the date of 
last follow-up or death. Progression-free survival (PFS) 
was calculated from the date of diagnosis to the time 
of progression or death. Kaplan-Meier survival curves 
were used to estimate OS and PFS rates, and the log-
rank (Mantel-Cox) test was used to assess differences in 
survival between groups. Multivariate analysis for survival 
was performed with IBM statistics SPSS 19 software using 
the Cox proportional hazards regression model  (Chicago, 
SPSS Inc.). All differences with P≤0.05 were considered 
to be statistically significant.
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